An Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Maribavir in Chinese Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Cidofovir or Foscarnet
Latest Information Update: 08 Mar 2025
At a glance
- Drugs Maribavir (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Registrational
- Sponsors Takeda
Most Recent Events
- 28 Feb 2025 Planned End Date changed from 5 Feb 2027 to 31 Dec 2026.
- 28 Feb 2025 Planned primary completion date changed from 5 Feb 2027 to 31 Dec 2026.
- 26 Feb 2025 Status changed from not yet recruiting to recruiting.